Antisoma announces the successful completion of a phase I trial of R1550 (huHMFG1) and presentation of its results today at the ASCO meeting in Atlanta. The safety study in patients with metastatic (spreading) breast cancer showed that the drug was well tolerated at the maximum dose tested, clearing the way for further development in patients with less advanced disease. While analysis of efficacy was not a primary aim, a number of patients showed prolonged stabilisation of disease.
